High cutaneous amphiregulin expression predicts fatal acute graft-versus-host disease

J Cutan Pathol. 2022 Jun;49(6):532-535. doi: 10.1111/cup.14218. Epub 2022 Mar 13.

Abstract

Background: Amphiregulin (AREG) is increased in circulation in acute graft-versus-host disease (aGVHD) and is associated with poor steroid response and lower survival. The expression of AREG in aGVHD target organs and its association with clinical outcomes are unknown.

Methods: We performed AREG immunohistochemical staining on skin specimens from 67 patients with aGVHD between the years 2010 and 2015. Two blinded reviewers assessed AREG expression and scored specimens with a semiquantitative scale ranging from 0 (absent) to 4 (most intense).

Results: Median AREG score of aGVHD cases was 3. Sixteen of 67 (23.9%) aGVHD cases had an AREG >3. High skin AREG expression (>3 vs. ≤3) was associated with increased overall clinical grade of aGVHD (52.9% vs. 33.4% clinical grade III-IV, p = 0.02), reduced 3-year overall survival (OS; 13% vs. 61%, p < 0.01), and increased 3-year non-relapse mortality (NRM; 56% vs. 20%, p = 0.05).

Conclusion: High skin AREG immunohistochemical expression is associated with high clinical grade aGVHD, poor OS, and increased NRM.

Keywords: acute GVHD; allogeneic hematopoietic cell transplantation; amphiregulin; epidermal growth factor.

MeSH terms

  • Acute Disease
  • Amphiregulin* / analysis
  • Graft vs Host Disease* / diagnosis
  • Graft vs Host Disease* / mortality
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Neoplasm Recurrence, Local
  • Skin* / metabolism
  • Steroids

Substances

  • AREG protein, human
  • Amphiregulin
  • Steroids